What is Nectin Therapeutics?
Nectin Therapeutics operates at the intersection of advanced molecular biology and clinical oncology. The company is dedicated to transforming cancer care by targeting the nectin pathway, a critical area of interest for overcoming resistance in existing immuno-oncology therapies. By developing a robust portfolio of differentiated therapeutic candidates, Nectin aims to establish new benchmarks for efficacy and patient response rates. The firm is supported by a leadership team with a proven track record in biotechnology, ensuring that its scientific insights are translated into viable, market-ready medical solutions. As a venture-backed entity, Nectin maintains a lean, high-impact operational model that prioritizes rapid iteration and rigorous clinical validation.
How much funding has Nectin Therapeutics raised?
Nectin Therapeutics has raised a total of $25M across 1 funding round:
Series A
$25M
Series A (2022): $25M with participation from IBF, aMoon Fund, and Peregrine Ventures
Key Investors in Nectin Therapeutics
Peregrine Ventures
Peregrine is dedicated to advancing medical innovation through global strategic investments, focusing on life science companies at various stages of development.
aMoon Fund
A leading health-tech and life sciences venture capital firm that invests in companies with the potential to transform global healthcare.
IBF
An investment firm focused on identifying and supporting high-growth biotechnology and medical device companies with disruptive potential.
What's next for Nectin Therapeutics?
With the recent capital infusion, Nectin Therapeutics is poised to scale its research and development operations significantly. The strategic roadmap likely involves advancing its lead candidates through preclinical and clinical milestones, while simultaneously expanding its intellectual property portfolio. Given the current market appetite for innovative oncology assets, the company is well-positioned to pursue further partnerships or licensing agreements that could amplify the reach of its therapeutic pipeline. Future growth will be defined by the firm's ability to demonstrate superior clinical outcomes, thereby solidifying its status as a leader in the competitive immuno-oncology landscape and potentially attracting further institutional backing as it approaches later-stage development.
See full Nectin Therapeutics company page
